Krishna Nalleballe
Concepts (151)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 14 | 2022 | 492 | 2.620 |
Why?
| Thrombolytic Therapy | 4 | 2022 | 110 | 1.300 |
Why?
| Pneumonia, Viral | 6 | 2020 | 168 | 1.290 |
Why?
| Fibrinolytic Agents | 4 | 2022 | 124 | 1.290 |
Why?
| Coronavirus Infections | 6 | 2020 | 177 | 1.270 |
Why?
| Tissue Plasminogen Activator | 3 | 2020 | 109 | 1.250 |
Why?
| Endovascular Procedures | 2 | 2022 | 173 | 0.840 |
Why?
| Pandemics | 8 | 2020 | 559 | 0.840 |
Why?
| Cavernous Sinus | 1 | 2022 | 15 | 0.800 |
Why?
| Carotid-Cavernous Sinus Fistula | 1 | 2022 | 11 | 0.800 |
Why?
| Conflict of Interest | 2 | 2020 | 25 | 0.740 |
Why?
| Embolization, Therapeutic | 1 | 2022 | 88 | 0.740 |
Why?
| Iodine Compounds | 1 | 2020 | 7 | 0.720 |
Why?
| Brain Edema | 1 | 2020 | 41 | 0.700 |
Why?
| Brain Ischemia | 4 | 2022 | 161 | 0.650 |
Why?
| Mucopolysaccharidosis II | 1 | 2018 | 1 | 0.650 |
Why?
| Contrast Media | 1 | 2020 | 184 | 0.640 |
Why?
| Cardiology | 1 | 2020 | 89 | 0.640 |
Why?
| Medicare | 1 | 2020 | 246 | 0.640 |
Why?
| Coronary Angiography | 1 | 2020 | 334 | 0.630 |
Why?
| Physicians | 1 | 2020 | 233 | 0.570 |
Why?
| Hospitalization | 6 | 2022 | 652 | 0.500 |
Why?
| Databases, Factual | 3 | 2020 | 658 | 0.430 |
Why?
| Telemedicine | 1 | 2019 | 448 | 0.420 |
Why?
| Humans | 29 | 2022 | 49974 | 0.420 |
Why?
| Headache | 2 | 2022 | 76 | 0.370 |
Why?
| Aged | 10 | 2021 | 9310 | 0.370 |
Why?
| Time Factors | 4 | 2020 | 2903 | 0.360 |
Why?
| Autoimmune Diseases | 2 | 2020 | 101 | 0.340 |
Why?
| Ischemic Attack, Transient | 2 | 2020 | 56 | 0.340 |
Why?
| Immunosuppressive Agents | 2 | 2020 | 221 | 0.330 |
Why?
| United States | 6 | 2020 | 4860 | 0.310 |
Why?
| Female | 16 | 2021 | 26472 | 0.290 |
Why?
| Male | 14 | 2021 | 25241 | 0.270 |
Why?
| Arkansas | 4 | 2019 | 1977 | 0.270 |
Why?
| Middle Aged | 11 | 2021 | 12069 | 0.260 |
Why?
| Emergency Service, Hospital | 2 | 2020 | 486 | 0.260 |
Why?
| Tomography, X-Ray Computed | 2 | 2020 | 1159 | 0.230 |
Why?
| Triage | 2 | 2021 | 62 | 0.230 |
Why?
| Thrombectomy | 2 | 2020 | 67 | 0.220 |
Why?
| Drug Industry | 2 | 2020 | 38 | 0.220 |
Why?
| Neuroimaging | 2 | 2020 | 84 | 0.220 |
Why?
| Critical Care | 2 | 2021 | 213 | 0.200 |
Why?
| Retrospective Studies | 5 | 2020 | 6108 | 0.200 |
Why?
| Sinus Thrombosis, Intracranial | 1 | 2021 | 17 | 0.190 |
Why?
| Myasthenia Gravis | 1 | 2021 | 17 | 0.190 |
Why?
| Hospitalists | 1 | 2020 | 11 | 0.190 |
Why?
| Intracranial Thrombosis | 1 | 2020 | 16 | 0.190 |
Why?
| Ageusia | 1 | 2020 | 6 | 0.180 |
Why?
| Olfaction Disorders | 1 | 2020 | 7 | 0.180 |
Why?
| Neuromuscular Diseases | 1 | 2020 | 30 | 0.180 |
Why?
| Osmolar Concentration | 1 | 2020 | 62 | 0.180 |
Why?
| Health Services Misuse | 1 | 2020 | 13 | 0.180 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2020 | 60 | 0.180 |
Why?
| Multiple Sclerosis | 1 | 2020 | 66 | 0.180 |
Why?
| Health Care Sector | 1 | 2020 | 15 | 0.180 |
Why?
| Time-to-Treatment | 1 | 2020 | 61 | 0.180 |
Why?
| Neurologic Examination | 1 | 2020 | 77 | 0.180 |
Why?
| Infarction, Middle Cerebral Artery | 1 | 2020 | 40 | 0.180 |
Why?
| Mood Disorders | 1 | 2020 | 59 | 0.180 |
Why?
| Young Adult | 2 | 2020 | 3958 | 0.170 |
Why?
| Patient Transfer | 1 | 2020 | 94 | 0.170 |
Why?
| Brain Diseases | 1 | 2020 | 82 | 0.170 |
Why?
| Venous Thrombosis | 1 | 2020 | 90 | 0.170 |
Why?
| Subarachnoid Hemorrhage | 1 | 2020 | 65 | 0.170 |
Why?
| Drug-Eluting Stents | 1 | 2020 | 93 | 0.170 |
Why?
| Suicidal Ideation | 1 | 2020 | 96 | 0.170 |
Why?
| Fabry Disease | 1 | 2019 | 9 | 0.170 |
Why?
| Enzyme Replacement Therapy | 1 | 2019 | 17 | 0.170 |
Why?
| Recombinant Fusion Proteins | 1 | 2010 | 181 | 0.170 |
Why?
| Fluorocarbons | 1 | 2019 | 45 | 0.170 |
Why?
| Hospitals | 1 | 2020 | 175 | 0.170 |
Why?
| Nervous System Diseases | 1 | 2020 | 88 | 0.160 |
Why?
| Tomography Scanners, X-Ray Computed | 1 | 2018 | 12 | 0.160 |
Why?
| Aged, 80 and over | 3 | 2020 | 3129 | 0.160 |
Why?
| Angiogenesis Inhibitors | 1 | 2010 | 187 | 0.160 |
Why?
| Angiography, Digital Subtraction | 1 | 2018 | 27 | 0.160 |
Why?
| Neuroprotective Agents | 1 | 2019 | 105 | 0.160 |
Why?
| Seizures | 1 | 2020 | 195 | 0.160 |
Why?
| Anxiety | 1 | 2020 | 274 | 0.150 |
Why?
| Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 130 | 0.150 |
Why?
| Pain | 1 | 2020 | 379 | 0.150 |
Why?
| Meningitis | 1 | 2016 | 24 | 0.140 |
Why?
| Referral and Consultation | 1 | 2019 | 285 | 0.140 |
Why?
| Diagnosis, Differential | 1 | 2020 | 1037 | 0.140 |
Why?
| Myocardial Infarction | 1 | 2020 | 389 | 0.140 |
Why?
| Antibodies, Monoclonal | 1 | 2010 | 459 | 0.130 |
Why?
| Percutaneous Coronary Intervention | 1 | 2020 | 297 | 0.130 |
Why?
| Ovarian Neoplasms | 1 | 2010 | 447 | 0.130 |
Why?
| Plasma Cells | 1 | 2016 | 223 | 0.130 |
Why?
| Magnetic Resonance Imaging | 2 | 2020 | 1537 | 0.120 |
Why?
| Adult | 5 | 2020 | 13236 | 0.120 |
Why?
| RNA-Directed DNA Polymerase | 1 | 2002 | 6 | 0.110 |
Why?
| Oligodeoxyribonucleotides | 1 | 2002 | 29 | 0.110 |
Why?
| DNA, Complementary | 1 | 2002 | 135 | 0.100 |
Why?
| Adolescent | 2 | 2020 | 6356 | 0.100 |
Why?
| Antineoplastic Agents | 1 | 2010 | 1171 | 0.100 |
Why?
| Mycobacterium tuberculosis | 1 | 2002 | 285 | 0.090 |
Why?
| Treatment Outcome | 4 | 2022 | 5141 | 0.090 |
Why?
| Intubation, Intratracheal | 2 | 2021 | 118 | 0.080 |
Why?
| Cohort Studies | 2 | 2022 | 1422 | 0.070 |
Why?
| Prevalence | 2 | 2020 | 944 | 0.070 |
Why?
| Risk Factors | 2 | 2022 | 3613 | 0.050 |
Why?
| Intracranial Hemorrhages | 1 | 2022 | 38 | 0.050 |
Why?
| Multiple Myeloma | 1 | 2016 | 2929 | 0.050 |
Why?
| Cerebral Hemorrhage | 1 | 2022 | 104 | 0.050 |
Why?
| Cranial Sinuses | 1 | 2021 | 10 | 0.050 |
Why?
| Industry | 1 | 2020 | 17 | 0.050 |
Why?
| Arthritis, Psoriatic | 1 | 2020 | 9 | 0.050 |
Why?
| Spondylitis, Ankylosing | 1 | 2020 | 9 | 0.050 |
Why?
| Cranial Nerves | 1 | 2020 | 14 | 0.050 |
Why?
| Disease Susceptibility | 1 | 2021 | 89 | 0.050 |
Why?
| Endocrine System Diseases | 1 | 2010 | 10 | 0.040 |
Why?
| Colitis, Ulcerative | 1 | 2020 | 50 | 0.040 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2010 | 22 | 0.040 |
Why?
| Mortality | 1 | 2020 | 99 | 0.040 |
Why?
| Arthritis, Rheumatoid | 1 | 2020 | 105 | 0.040 |
Why?
| Registries | 1 | 2022 | 522 | 0.040 |
Why?
| Maximum Tolerated Dose | 1 | 2019 | 37 | 0.040 |
Why?
| Crohn Disease | 1 | 2020 | 90 | 0.040 |
Why?
| Tertiary Care Centers | 1 | 2019 | 77 | 0.040 |
Why?
| Administration, Oral | 1 | 2020 | 426 | 0.040 |
Why?
| alpha-Galactosidase | 1 | 2019 | 9 | 0.040 |
Why?
| Disease Outbreaks | 1 | 2020 | 125 | 0.040 |
Why?
| Administration, Intravenous | 1 | 2019 | 69 | 0.040 |
Why?
| Disability Evaluation | 1 | 2019 | 87 | 0.040 |
Why?
| Hemorrhage | 1 | 2020 | 197 | 0.040 |
Why?
| Skin Diseases | 1 | 2010 | 112 | 0.040 |
Why?
| Gastrointestinal Diseases | 1 | 2010 | 126 | 0.040 |
Why?
| Electronic Health Records | 1 | 2021 | 209 | 0.040 |
Why?
| Drug Administration Schedule | 1 | 2019 | 376 | 0.040 |
Why?
| Recovery of Function | 1 | 2019 | 188 | 0.040 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 225 | 0.040 |
Why?
| Comorbidity | 1 | 2019 | 615 | 0.040 |
Why?
| Patient Readmission | 1 | 2019 | 219 | 0.040 |
Why?
| Double-Blind Method | 1 | 2019 | 681 | 0.040 |
Why?
| Prognosis | 1 | 2022 | 1942 | 0.040 |
Why?
| Fatal Outcome | 1 | 2016 | 195 | 0.030 |
Why?
| Follow-Up Studies | 1 | 2020 | 2182 | 0.030 |
Why?
| Risk Assessment | 1 | 2019 | 1259 | 0.030 |
Why?
| Cardiovascular Diseases | 1 | 2010 | 440 | 0.030 |
Why?
| Prospective Studies | 1 | 2020 | 2364 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2019 | 1557 | 0.030 |
Why?
| DNA Primers | 1 | 2002 | 207 | 0.030 |
Why?
| Infant | 1 | 2020 | 3567 | 0.030 |
Why?
| Child, Preschool | 1 | 2020 | 3871 | 0.020 |
Why?
| Transcription, Genetic | 1 | 2002 | 369 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 411 | 0.020 |
Why?
| Gene Expression Regulation, Bacterial | 1 | 2002 | 191 | 0.020 |
Why?
| RNA, Messenger | 1 | 2002 | 1105 | 0.020 |
Why?
| Child | 1 | 2020 | 6847 | 0.020 |
Why?
|
|
Nalleballe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|